Senti Biosciences

Senti Biosciences, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation cell and gene therapies engineered with proprietary gene circuit technologies. Founded in 2016 and headquartered in South San Francisco, California, the company leverages synthetic biology to program cells with 'logic gates' that enable them to sense, compute, and respond to their environment. This innovative approach aims to overcome the limitations of current therapeutic modalities by enhancing the precision, control, and efficacy of treatments for complex diseases, particularly in the field of oncology.

The company's core technology platform focuses on designing synthetic gene circuits, such as Logic Gates, Smart Sensors, and Regulator Dials, which are integrated into cell therapies. These circuits allow for the creation of 'smarter' medicines capable of distinguishing between diseased and healthy cells, thereby potentially reducing off-target toxicity and improving patient safety. Senti Biosciences is currently advancing a pipeline of off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy candidates. Its lead program, SENTI-202, is designed to selectively target and eliminate cancer cells in patients with acute myeloid leukemia (AML) while sparing healthy bone marrow cells. Through its pioneering work in synthetic biology, Senti Biosciences strives to deliver transformative treatments that address significant unmet medical needs.